Pfizer is a research-based biopharmaceutical company. The company's portfolio includes medicines and vaccines, as well as consumer healthcare products. The company manages its commercial operations through three businesses: Pfizer Biopharmaceuticals Group, which includes the company's health business units (except Consumer Healthcare) as well as a hospital business unit that commercializes its portfolio of sterile injectable and anti-infective medicines; Upjohn, which includes the company's solid oral dose brands such as Lyrica, Lipitor, Norvasc, Viagra and Celebrex, as well as certain generic medicines; and Consumer Healthcare, which is an over-the-counter medicines business.
  • TickerPFE
  • ISINUS7170811035
  • ExchangeNew York Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-term ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Valérie GASTALDY

Short term view - PFIZER INC : The background trend is clearly bullish.

The background trend is clearly bullish. The recent fall is a consolidation that may be interrupted as it approaches de $42.41. The next target is at $44.20. The trend would be invalidated below the support at $41.10.

Stocks Remain Trend Down Into Election Vol (GMR Weekly Notes - 5 Nov 2018)

Markets This Week: Stocks: Novartis (NVS); Allergan (AGN); Pfizer (PFE); XPO Logistics (XPO); Tencent Holdings (TCEHY); Walmart (WMT) Forex: EURNZD; USDSGD; NOKSEK; XAUJPY Rates: EDZ9; Bunds (GDBR10) Commodities: Brent Crude (CO1)

Macro Technicals - 4 December 2017

Pfizer (PFE) set up for sharp directionnal move into year-end, 2018.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Valens Research

Valens Equity Insights and Inflections - 2020 01 21

RBC currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 14.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from 14% in 2018 to 11% in 2023, accompanied by immaterial Uniform Asset growth going forward. However, analysts have bullish expectations, projecting Uniform ROA to improve to 15% through 2020, accompanied by 9% Uniform Asset shrinkage. Meanwhile, management is confident about their growth potential, leverage levels, and the progress of restructuring efforts. Current valuations appear to be pricing...

Valens Research

PFE - Embedded Expectations Analysis - 2020 01 15

 Pfizer Inc. (PFE:USA) currently trades near recent averages relative to UAFRS-based (Uniform) Earnings, with a 15.1x Uniform P/E. At these levels, the market has bearish expectations for the firm, and management may be concerned about biopharma growth, the strength of their pipeline, and oncology biosimilar launches  Specifically, management may lack confidence in their ability to sustain growth in Ibrance and their biopharma business, find accretive bolt-on acquisition opportunities, and manage SI&A expenses. Furthermore, they may be exaggerating expectations for 2019 revenue and EPS, the ...

MarketLine Department

Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report

Summary Sanofi Genzyme - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Sanofi Genzyme (Genzyme), a specialty care global business unit of Sanofi provides treatments with a focus on rare diseases, multiple sclerosis, immunology, and oncology. The major products of the company include Aldurazyme, Aubagio, Caprelsa tablets, Cerdelga capsules, Cerezyme, Clolar, Dupi...

Pfizer Inc. - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's assigns A1 to Pfizer's notes; on review for downgrade

Rating Action: Moody's assigns A1 to Pfizer's notes; on review for downgrade. Global Credit Research- 18 May 2020. New York, May 18, 2020-- Moody's Investors Service assigned an A1 rating to the new senior unsecured notes being issued by Pfizer Inc..

Pfizer Inc. - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's assigns A1 to Pfizer's notes, on review for downgrade

Rating Action: Moody's assigns A1 to Pfizer's notes, on review for downgrade. Global Credit Research- 25 Mar 2020. New York, March 25, 2020-- Moody's Investors Service assigned an A1 rating to the new senior unsecured notes being issued by Pfizer Inc..

Pfizer Inc.: Update to credit analysis - rating review continues with Upjohn separation pending

Our credit view of Pfizer reflecting large scale, good diversity and high margins, offset by modest financial leverage and reduced free cash flow ensuing from the pending Upjohn separation.

PFIZER INCO. sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of PFIZER INCO. (US), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 3 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date April 10, 2020, the closing price was USD 35.39 and its potential was estimated at USD 37.99.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch